Related Experiment Video

Updated: Jun 12, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Herpes simplex virus oncolytic vaccine therapy in melanoma

Shanthi Sivendran1, Michael Pan, Howard L Kaufman

  • 1The Mount Sinai School of Medicine, The Tisch Cancer Institute, Division of Hematology/Oncology, Department of Medicine, New York, NY 10029, USA.

Expert Opinion on Biological Therapy
|June 3, 2010
PubMed
Abstract

Insights

A novel herpes simplex virus-1 oncolytic vaccine, JSI/34.5-/47-/GM-CSF, shows promise in treating advanced melanoma by inducing both local tumor destruction and systemic immune responses. Early clinical trials indicate durable regressions and limited toxicity, suggesting a new therapeutic avenue.

Area of Science:

  • Oncolytic virotherapy
  • Cancer immunotherapy
  • Melanoma treatment

Background:

  • Advanced melanoma has poor prognosis with current therapies offering limited efficacy.
  • There is a critical need for novel therapeutic strategies to improve survival rates.
  • JSI/34.5-/47-/GM-CSF is an oncolytic vaccine designed to elicit anti-tumor immune responses.

Purpose of the Study:

  • To review the development of herpes simplex virus oncolytic vaccines.
  • To evaluate the preclinical and clinical data of JSI/34.5-/47-/GM-CSF.
  • To assess the potential of this therapy in advanced cancers.

Main Methods:

  • Review of preclinical studies on herpes simplex virus-1 (HSV-1) oncolytic vaccines.
  • Analysis of Phase I and II clinical trial data for JSI/34.5-/47-/GM-CSF.
  • Overview of ongoing Phase III trials in melanoma and head and neck cancer.

Main Results:

  • Preclinical studies confirm HSV-1 oncolytic vaccines induce tumor lysis and immune responses.
  • Phase I trials showed minimal toxicity, with no neurotoxicity observed.
  • Phase II trials demonstrated durable regressions in metastatic melanoma patients.
  • Ongoing Phase III trials aim to confirm clinical effectiveness.

Conclusions:

  • JSI/34.5-/47-/GM-CSF represents a new generation of HSV-1 oncolytic vaccine.
  • This therapy combines direct tumor cell killing with the induction of systemic anti-tumor immunity.
  • Early clinical data suggest promising therapeutic activity for advanced cancers.

More Related Videos

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Herpes01:28

Herpes

Herpes simplex type 1 (HSV‑1) is a widespread pathogen responsible for orolabial lesions. It is an enveloped, double-stranded DNA (dsDNA) virus belonging to the family Herpesviridae. Once the virus infects a host cell, its double‑stranded DNA genome is delivered into the nucleus, where a coordinated cascade of immediate‑early, early, and late gene expression directs viral DNA replication, structural protein synthesis, and virion assembly. After primary infection of epithelial cells, HSV-1...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Genital Herpes01:23

Genital Herpes

Genital herpes is a sexually transmitted infection primarily caused by herpes simplex virus type 2 (HSV-2), though herpes simplex virus type 1 (HSV-1) is increasingly implicated in genital infections, particularly among younger populations. Transmission occurs mainly through sexual contact, with asymptomatic viral shedding serving as a major route of spread. This characteristic makes HSV-2 difficult to control at a population level, as individuals may unknowingly transmit the virus even in the...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...